Target intelligence / Profile preview

Severe acute respiratory syndrome coronavirus 2 (whole virion) (SARS-CoV-2 (whole virion))

Target
SARS-CoV-2 (whole virion)
Molecular classification
Virus, Enveloped virus, Betacoronavirus
01

Overview

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense single-stranded RNA virus belonging to the Betacoronavirus genus and is the causative agent of COVID-19[2][4]. The whole virion consists of an approximately 100 nm spherical particle composed of a lipid envelope embedded with spike (S), envelope (E), and membrane (M) proteins, surrounding a nucleocapsid (N)-encapsidated ~30 kb RNA genome[2][1]. The spike glycoprotein mediates binding to host angiotensin-converting enzyme 2 (ACE2) receptors, enabling viral entry and fusion with host cell membranes[2][3][4]. SARS-CoV-2 whole virion is a therapeutic target for antiviral drugs, neutralizing antibodies, and vaccines, with major structural proteins serving as primary antigens and antiviral target sites. The virus is the agent of the global COVID-19 pandemic, with infection leading to a range of outcomes from mild respiratory symptoms to severe pneumonia and systemic inflammatory responses[2][4].

Other names
SARS-CoV-2 virionSARS-CoV-2Novel coronavirus 20192019-nCoV
02

Mechanism of action

Inhibition of viral RNA-dependent RNA polymerase (e.g., remdesivir, molnupivir); Inhibition of main viral protease (nirmatrelvir); Neutralizing antibody-mediated inhibition of viral entry (monoclonal antibodies, vaccine-induced antibodies); Induction of immune response to viral proteins (vaccines)

03

Biological functions

InfectionViral replicationImmune response modulation
04

Disease associations

InfectionCOVID-19
05

Safety considerations

High infectivityMutational diversity leading to immune escapeAntibody-dependent enhancement (potential risk, rare)Cytokine storm (complication of infection)
06

Interacting drugs

Remdesivir

4 more in the full profile.

07

Biomarkers

Viral RNA (PCR detection)SARS-CoV-2 specific antibodies (IgG, IgM, IgA)Nucleocapsid protein (N antigen tests)

Beyond the preview

Go deeper on Severe acute respiratory syndrome coronavirus 2 (whole virion) (SARS-CoV-2 (whole virion)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Severe acute respiratory syndrome coronavirus 2 (whole virion) (SARS-CoV-2 (whole virion)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call